
Ampio Pharmaceuticals AMPE
Annual report 2023
added 03-27-2024
Ampio Pharmaceuticals Total Shareholders Equity 2011-2026 | AMPE
Annual Total Shareholders Equity Ampio Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.36 M | 11.8 M | 27.3 M | 17.5 M | 6.44 M | 5.24 M | -34.2 M | 6.63 M | 37 M | 66.1 M | 33.1 M | 23.8 M | 17.8 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 66.1 M | -34.2 M | 17.1 M |
Quarterly Total Shareholders Equity Ampio Pharmaceuticals
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.38 M | 6.56 M | 7.88 M | 11.8 M | 13.8 M | 20.1 M | 22.3 M | 27.3 M | 17.3 M | 20.3 M | 16.8 M | 17.5 M | 17.5 M | 17.5 M | 17.5 M | 6.44 M | 6.44 M | 6.44 M | 6.44 M | 5.24 M | 5.24 M | 5.24 M | 5.24 M | -34.2 M | -34.2 M | -34.2 M | 5 M | 6.63 M | 9.77 M | 13.1 M | 17.9 M | 37 M | 37 M | 37 M | 37 M | 66.1 M | 66.1 M | 66.1 M | 66.1 M | 33.1 M | 33.1 M | 33.1 M | 33.1 M | 23.8 M | 23.8 M | 23.8 M | 23.8 M | 17.8 M | 17.8 M | 17.8 M | 17.8 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 66.1 M | -34.2 M | 18.6 M |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M | ||
|
Amgen
AMGN
|
8.66 B | $ 349.77 | 0.57 % | $ 188 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
789 M | $ 19.23 | -1.38 % | $ 899 M | ||
|
Altimmune
ALT
|
225 M | $ 3.44 | 2.99 % | $ 303 M | ||
|
Autolus Therapeutics plc
AUTL
|
427 M | $ 1.4 | 2.19 % | $ 357 M | ||
|
Aytu BioScience
AYTU
|
19 M | $ 2.63 | 0.77 % | $ 16.5 M | ||
|
I-Mab
IMAB
|
1.72 B | - | - | $ 866 M | ||
|
Genfit SA
GNFT
|
-16.2 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M | ||
|
Ascendis Pharma A/S
ASND
|
884 M | $ 218.06 | -1.72 % | $ 5 B | ||
|
Midatech Pharma plc
MTP
|
6.72 M | - | -18.52 % | $ 27.3 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | ||
|
ARCA biopharma
ABIO
|
382 M | - | 1052.0 % | $ 415 M | ||
|
Benitec Biopharma
BNTC
|
97.3 M | $ 11.19 | 1.91 % | $ 461 M | ||
|
AgeX Therapeutics
AGE
|
5.47 M | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
-158 M | - | -24.86 % | $ 820 K | ||
|
Albireo Pharma
ALBO
|
176 M | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
54.4 M | - | 10.36 % | $ 9.8 M | ||
|
Compugen Ltd.
CGEN
|
103 M | $ 2.09 | - | $ 195 M | ||
|
Acasti Pharma
ACST
|
66.6 M | - | 4.01 % | $ 150 M | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
13.5 M | $ 0.61 | -1.3 % | $ 6.99 M | ||
|
Avenue Therapeutics
ATXI
|
2.8 M | - | -52.27 % | $ 4.45 M | ||
|
Adverum Biotechnologies
ADVM
|
70.7 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
-16.8 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
-24.4 M | - | -9.65 % | $ 45.9 M | ||
|
Cellectis S.A.
CLLS
|
309 M | $ 3.42 | 2.4 % | $ 116 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-1.1 M | - | - | $ 7.46 M | ||
|
Cullinan Management
CGEM
|
409 M | $ 12.84 | 0.78 % | $ 774 M | ||
|
Atreca
BCEL
|
78.4 M | - | -11.76 % | $ 5.79 M | ||
|
BioDelivery Sciences International
BDSI
|
188 M | - | -4.8 % | $ 255 M | ||
|
BeiGene, Ltd.
BGNE
|
4.36 B | - | 0.49 % | $ 251 B | ||
|
Calithera Biosciences
CALA
|
8.38 M | - | -10.95 % | $ 876 K | ||
|
CorMedix
CRMD
|
405 M | $ 6.42 | 2.72 % | $ 462 K | ||
|
Cara Therapeutics
CARA
|
57.1 M | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
286 M | - | - | $ 3.74 B | ||
|
Bellerophon Therapeutics
BLPH
|
2.53 M | - | -74.18 % | $ 955 K | ||
|
Checkpoint Therapeutics
CKPT
|
-12.6 M | - | - | $ 169 M | ||
|
Clovis Oncology
CLVS
|
-279 M | - | -7.23 % | $ 13 M | ||
|
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | ||
|
Denali Therapeutics
DNLI
|
1.23 B | $ 21.09 | 4.56 % | $ 3.47 B | ||
|
Dyadic International
DYAI
|
5.88 M | $ 0.86 | -8.51 % | $ 24.8 M | ||
|
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
106 M | $ 4.42 | 4.25 % | $ 734 M | ||
|
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | ||
|
AIkido Pharma
AIKI
|
39.9 M | - | 1.93 % | $ 17.4 M |